{
    "name": "ibuprofen/famotidine",
    "comment": "Rx",
    "other_names": [
        "Duexis"
    ],
    "classes": [
        "NSAIDs"
    ],
    "source": "https://reference.medscape.com/drug/duexis-ibuprofen-famotidine-999647",
    "pregnancy": {
        "common": [
            "Use of NSAIDs can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment",
            "Because of these risks, limit dose and duration of use between about 20 and 30 weeks of gestation and avoid use at about 30 weeks of gestation and later in pregnancy",
            "Use of NSAIDs at about 30 weeks gestation or later in pregnancy increases risk of premature closure of fetal ductus arteriosus",
            "Use of NSAIDs at about 20 weeks gestation or later in pregnancy has been associated with cases of fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment",
            "There are no available data with use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage; however, there are published studies with each individual component of the drug combination"
        ],
        "specific": [
            {
                "type": "Ibuprofen",
                "description": [
                    "Data from observational studies regarding potential embryofetal risks of NSAID use in women in the first or second trimesters of pregnancy are inconclusive",
                    "In animal reproduction studies, there were no clear developmental effects at doses up to 0.4-times the maximum recommended human dose (MRHD) in the rabbit and 0.5-times in the MRHD rat when dosed throughout gestation",
                    "In contrast, an increase in membranous ventricular septal defects was reported in rats treated on gestation days 9 & 10 with 0.8-times the MRHD",
                    "Based on animal data, prostaglandins have been shown to have an important role in endometrial vascular permeability, blastocyst implantation, and decidualization. In animal studies, administration of prostaglandin synthesis inhibitors such as ibuprofen, resulted in increased pre-and post-implantation loss",
                    "Prostaglandins also have been shown to have an important role in fetal kidney development; in published animal studies, prostaglandin synthesis inhibitors have been reported to impair kidney development when administered at clinically relevant doses"
                ]
            },
            {
                "type": "Famotidine",
                "description": [
                    "Limited published data do not report an increased risk of congenital malformations or other adverse pregnancy effects with use of H2-receptor antagonists during pregnancy; however, these data are insufficient to adequately determine a drug-associated risk",
                    "Reproductive studies with famotidine have been performed in rats and rabbits at oral doses of up to 2000 and 500 mg/kg/day (approximately 243 and 122 times the recommended human dose, respectively, based on body surface area) and in both species at intravenous (IV) doses of up to 200 mg/kg/day, and have revealed no significant evidence of impaired fertility or harm to the fetus due to famotidine",
                    "Avoid use of NSAIDs in women at about 30 weeks gestation and later in pregnancy, because NSAIDs, can cause premature closure of fetal ductus arteriosus",
                    "If an NSAID is necessary at about 20 weeks gestation or later in pregnancy, limit use to lowest effective dose and shortest duration possible",
                    "If treatment is needed for a pregnant woman, consider monitoring with ultrasound for oligohydramnios; if oligohydramnios occurs, discontinue therapy and follow up according to clinical practice"
                ]
            },
            {
                "type": "Labor or Delivery",
                "description": [
                    "There are no studies on the effects of drug combination during labor or delivery; in animal studies, NSAIDs, including ibuprofen, inhibit prostaglandin synthesis, cause delayed parturition, and increase the incidence of stillbirth."
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "No studies conducted with use of drug combination in lactating women; limited data from published literature report famotidine is present in human milk in low amounts",
            "Published literature also reports the presence of ibuprofen in human milk in low amounts; no information is available on effects of famotidine or ibuprofen on milk production or on a breastfed infant",
            "Famotidine is present in milk of lactating rats; developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on breastfed infant from drug combination or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Cardiovascular risk ",
                    "description": [
                        "Contains ibuprofen; may increase the risk of serious CV thrombotic events, myocardial infarction, and stroke, which can be fatal; risk may increase with duration of use",
                        "Patients with CV disease or risk factors may be at greater risk",
                        "Contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery"
                    ]
                },
                {
                    "type": "Gastrointestinal risk ",
                    "description": [
                        "NSAIDs, including ibuprofen, increase the risk of serious GI adverse reactions including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal",
                        "Reactions can occur at any time without warning symptoms",
                        "Elderly patients are at greater risk"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Pre-existing asthma, urticaria, or allergic reactions after taking aspirin or other NSAIDs",
                "Use during the perioperative period in the setting of CABG surgery",
                "Starting at 30 weeks gestation, NSAIDs should not be used by pregnant women as premature closure of the ductus arteriosus in the fetus may occur"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Therapy can lead to new onset of hypertension or worsening of pre-existing hypertension, either of which may contribute to increased incidence of CV events; patients taking angiotensin-converting enzyme (ACE) inhibitors, thiazide diuretics, or loop diuretics may have impaired response to these therapies when taking NSAIDs; monitor blood pressure (BP) during initiation of NSAID treatment and throughout course of therapy",
                "Fluid retention and edema can occur with NSAID treatment; use with caution in patients with fluid retention or heart failure; ibuprofen may blunt CV effects of several therapeutic agents used to treat medical conditions associated with fluid retention and edema (eg, diuretics, ACE inhibitors, or angiotensin receptor blockers [ARBs]); avoid use in patients with severe heart failure unless benefits expected to outweigh risk of worsening heart failure; if drug is used in patients with severe heart failure, monitor patients for signs and symptoms of worsening heart failure",
                "Antiplatelet effect; active and clinically significant bleeding from any source can occur; discontinue if active bleeding occurs; patients with initial hemoglobin values of 10 g or less who are to receive long-term therapy should have hemoglobin values determined periodically",
                "Long-term NSAID administration can result in renal papillary necrosis and other renal injury; caution in patients at risk (eg elderly, existing renal impairment, heart failure, liver impairment, coadministration with diuretics or ACE inhibitors)",
                "Anaphylaxis may occur; especially in asthmatic patients experiencing rhinitis and bronchospasm; discontinue immediately if an anaphylactoid reaction occurs",
                "A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps; severe, potentially fatal bronchospasm; and/or intolerance to aspirin and other NSAIDs; because cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, this drug is contraindicated in patients with this form of aspirin sensitivity; when used in patients with preexisting asthma (without known aspirin sensitivity), monitor patients for changes in the signs and symptoms of asthma",
                "Serious/fatal skin reactions may occur and include exfoliative dermatitis, Stevens-Johnson Syndrome, and toxic epidermal necrolysis; discontinue if rash or other signs of local skin reaction occur; inform patients about signs and symptoms of serious skin reactions and to discontinue use at first appearance of skin rash or any other sign of hypersensitivity; this drug is contraindicated in patients with previous serious skin reactions to NSAIDs",
                "Central nervous system (CNS) adverse effects including seizures, delirium, and coma reported with famotidine in patients with moderate (creatinine clearance <50 mL/min) and severe renal insufficiency (creatinine clearance <10mL/min); dosage of famotidine component this drug combination is fixed; therefore, this drug is not recommended in patients with creatinine clearance <50 mL/min",
                "The pharmacological activity of this drug in reducing inflammation, and possibly fever, may diminish utility of diagnostic signs in detecting infections",
                "Aseptic meningitis with fever and coma reported on rare occasions in patients on ibuprofen, which is a component of this drug combination; although it is probably more likely to occur in patients with systemic lupus erythematosus (SLE) and related connective tissue diseases, it has been reported in patients who do not have an underlying chronic disease; if signs or symptoms of meningitis develop in a patient on therapy, the possibility of it being related to ibuprofen should be considered",
                "Blurred and/or diminished vision, scotomata, and/or changes in color vision reported; if a patient develops such complaints while receiving therapy, the drug should be discontinued, and the patient have an ophthalmologic examination which includes central visual fields and color vision testing"
            ],
            "specific": [
                {
                    "type": "Hematologic toxicity",
                    "description": [
                        "Anemia reported in NSAID-treated patients; this may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis; if a patient treated with this drug has any signs or symptoms of anemia,monitor hemoglobin or hematocrit; therapy may increase risk of bleeding events",
                        "Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, and other anticoagulants, antiplatelet agents (eg, aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) may increase risk; monitor these patients for signs of bleeding"
                    ]
                },
                {
                    "type": "Renal toxicity and hyperkalemia",
                    "description": [
                        "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; renal toxicity seen in patients in whom renal prostaglandins have compensatory role in maintenance of renal perfusion; in these patients, administration of NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation; patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and elderly; discontinuation of NSAID therapy was usually followed by recovery to pretreatment state",
                        "Therapy may hasten progression of renal dysfunction in patients with pre-existing renal disease",
                        "Correct volume status in dehydrated or hypovolemic patients prior to initiating therapy; monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during therapy",
                        "Avoid use of drug in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal failure; if drug is used in patients with advanced renal disease, monitor patients for signs of worsening renal function",
                        "Increases in serum potassium concentration, including hyperkalemia, reported with use of NSAIDs, even in some patients without renal impairment; in patients with normal renal function, these effects have been attributed to ahyporeninemic-hypoaldosteronism state"
                    ]
                },
                {
                    "type": "Cardiovascular thromboembolic events",
                    "description": [
                        "Unclear that the risk for CV thrombotic events is similar for all NSAIDS; relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease",
                        "Increased risk of serious CV thrombotic events began as early as first weeks of treatment; increase in CV thrombotic risk observed most consistently at higher doses",
                        "To minimize potential risk for an adverse CV event in NSAID-treated patients, use lowest effective dose for shortest duration possible; physicians and patients should remain alert for development of such events, throughout entire treatment course, even in absence of previous CV symptoms; patients should be informed about symptoms of serious CV events and steps to take if they occur",
                        "There is no consistent evidence that concurrent use of aspirin mitigates increased risk of serious CV thrombotic events associated with NSAID use; concurrent use of aspirin and an NSAID, such as ibuprofen, increases risk of serious gastrointestinal GI events",
                        "Patients treated with NSAIDs in post-MI period may be at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in firstweek of treatment; although absolute rate of death have been shown to decline somewhat after first-year post-MI, increased relative risk of death in NSAID users have persisted over at least next four years of follow-up",
                        "Avoid the use of the drug in patients with a recent MI unless benefits are expected to outweigh risk of recurrent CV thrombotic events; if drug is used in patients with a recent MI, monitor patients for signs of cardiac ischemia"
                    ]
                },
                {
                    "type": "GI bleeding ulceration, and perforation",
                    "description": [
                        "Patients with prior history of peptic ulcer disease and/or GI bleeding who used NSAIDs shown to have >10-fold increased risk for developing a GI bleed compared to patients without these risk factors",
                        "Other factors that increase risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status",
                        "Most postmarketing reports of fatal GI events reported in elderly or debilitated patients; patients with advanced liver disease and/or coagulopathy are at increased risk for GI bleeding; NSAIDs should be given with care to patients with a history of inflammatory bowel disease (ulcerative colitis, Crohn’s disease) as their condition may be exacerbated"
                    ]
                },
                {
                    "type": "Minimizing GI risks",
                    "description": [
                        "Use the lowest effective dosage for shortest possible duration.",
                        "Avoid administration of more than one NSAID at a time.",
                        "Avoid use in patients at higher risk unless benefits expected to outweigh increased risk of bleeding; for such patients, as well as those with active GI bleeding, consider alternate therapies other than NSAIDs",
                        "Remain alert for signs and symptoms of GI ulceration and bleeding during NSAID therapy",
                        "If a serious GI adverse event is suspected, promptly initiate evaluation and treatment, and discontinue drug until serious GI adverse event ruled out",
                        "In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, monitor patients more closely for evidence of GI bleeding"
                    ]
                },
                {
                    "type": "Hepatic injury",
                    "description": [
                        "Elevations to liver failure can occur; elevations of ALT or AST (three or more times upper limit of normal [ULN]) reported in approximately 1% of NSAID-treated patients in clinical trials; rare, sometimes fatal, cases of severe hepatic injury, including fulminant hepatitis, liver necrosis, and hepatic failure reported ",
                        "Inform patients of warning signs and symptoms of hepatotoxicity (eg, nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and flu-like symptoms); if clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (eg, eosinophilia, rash, etc.), discontinue drug immediately, and perform clinical evaluation of the patient"
                    ]
                },
                {
                    "type": "Drug reaction with eosinophilia and systemic symptoms",
                    "description": [
                        "Drug Reaction reported in patients taking NSAIDs; some of these events have been fatal or life-threatening; DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling",
                        "Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis; sometimes symptoms of DRESS may resemble an acute viral infection",
                        "Eosinophilia is often present; because this disorder is variable in its presentation, other organ systems not noted here may be involved",
                        "Early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident; if such signs or symptoms are present, discontinue therapy and evaluate the patient immediately"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "atazanavir",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of atazanavir by  increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Atazanavir solubility decreases as pH increases. Substantially reduced plasma concentrations of atazanavir are expected if H2-receptor antagonists (H2RA) are coadministered. For treatment-naïve patients, take atazanavir simultaneously with the H2RA or at least 10 h afterwards. See dosage adjustment recommendations if coadministered in treatment-experienced patients."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bosutinib",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of bosutinib by  increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dapsone",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of dapsone by  increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dasatinib",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of dasatinib by  increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "digoxin",
            "description": {
                "common": "ibuprofen/famotidine will increase the level or effect of digoxin by  increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "indinavir",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of indinavir by  increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "itraconazole",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of itraconazole by  increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug.  Administer acid neutralizing medicines at least 2 hours before or 2 hours after the intake of itraconazole."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ketoconazole",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of ketoconazole by  increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of levoketoconazole by  increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mefloquine",
            "description": {
                "common": "mefloquine increases toxicity of ibuprofen/famotidine by QTc interval. Avoid or Use Alternate Drug. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "neratinib",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of neratinib by  increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nimodipine",
            "description": {
                "common": "ibuprofen/famotidine will increase the level or effect of nimodipine by  increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nisoldipine",
            "description": {
                "common": "ibuprofen/famotidine will increase the level or effect of nisoldipine by  increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nitrendipine",
            "description": {
                "common": "ibuprofen/famotidine will increase the level or effect of nitrendipine by  increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pazopanib",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of pazopanib by  increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Avoid coadministration of pazopanib with drugs that raise gastric pH; consider short-acting antacids in place of PPIs and H2 antagonists; separate antacid and pazopanib dosing by several hours"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pimozide",
            "description": {
                "common": "ibuprofen/famotidine, pimozide.\nEither increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ponatinib",
            "description": {
                "common": "ibuprofen/famotidine decreases levels of ponatinib by increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "risedronate",
            "description": {
                "common": "ibuprofen/famotidine will increase the level or effect of risedronate by  increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Applies only to delayed release formulation; accelerates pH-sensitive dissolution of delayed release risedronate"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "secretin",
            "description": {
                "common": "ibuprofen/famotidine, secretin. Other (see comment). Avoid or Use Alternate Drug. \nComment: Concomitant use of H2-receptor antagonists may cause a hyperresponse in gastrin secretion in response to stimulation testing with secretin, falsely suggesting gastrinoma. Discontinue H2-receptor antagonists at least 2 days before administering secretin to aid in the diagnosis of gastrinoma."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vandetanib",
            "description": {
                "common": "ibuprofen/famotidine, vandetanib.\nEither increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aliskiren",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of aliskiren by  Other (see comment). Use Caution/Monitor. In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs with drugs that affect RAAS may increase the risk of renal impairment (including acute renal failure) and cause loss of antihypertensive effect. Monitor renal function periodically."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ampicillin",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of ampicillin by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bimatoprost",
            "description": {
                "common": "bimatoprost, ibuprofen/famotidine. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "budesonide",
            "description": {
                "common": "ibuprofen/famotidine decreases effects of budesonide by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Enteric-coated budesonide dissolves at pH >5.5. Also, dissolution of extended-release budesonide tablets is pH dependent. Coadministration with drugs that increase gastric pH may cause these budesonide products to prematurely dissolve, and possibly affect release properties and absorption of the drug in the duodenum."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbonyl iron",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of carbonyl iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cefdinir",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of cefdinir by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cefditoren",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of cefditoren by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cefpodoxime",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of cefpodoxime by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cefuroxime",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of cefuroxime by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crizotinib",
            "description": {
                "common": "ibuprofen/famotidine decreases levels of crizotinib by increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Drugs that elevate the gastric pH may decrease the solubility of crizotinib and subsequently reduce its bioavailability. However, no formal studies have been conducted. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "ibuprofen/famotidine, cyclosporine.\nEither increases toxicity of the other by nephrotoxicity and/or ototoxicity. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dabrafenib",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of dabrafenib by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Drugs that alter upper GI tract pH (eg, PPIs, H2-blockers, antacids) may decrease dabrafenib solubility and reduce its bioavailability"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexmethylphenidate",
            "description": {
                "common": "ibuprofen/famotidine will increase the level or effect of dexmethylphenidate by  increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Applies only to extended release formulation"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erlotinib",
            "description": {
                "common": "ibuprofen/famotidine decreases levels of erlotinib by Other (see comment). Use Caution/Monitor. \nComment: Avoid combination when possible. If  concurrent use is required erlotinib should be taken 10 hours after a H2-antagonist and at least 2 hours before the next dose of H2-antagonist."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ferric carboxymaltose",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of ferric carboxymaltose by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ferric gluconate",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of ferric gluconate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ferric maltol",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of ferric maltol by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ferrous fumarate",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of ferrous fumarate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ferrous gluconate",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of ferrous gluconate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ferrous sulfate",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of ferrous sulfate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fish oil triglycerides",
            "description": {
                "common": "fish oil triglycerides will increase the level or effect of ibuprofen/famotidine by  anticoagulation. Use Caution/Monitor. Prolonged bleeding reported in patients taking antiplatelet agents or anticoagulants and oral omega-3 fatty acids. Periodically monitor bleeding time in patients receiving fish oil triglycerides and concomitant antiplatelet agents or anticoagulants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of fosamprenavir by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gefitinib",
            "description": {
                "common": "ibuprofen/famotidine decreases levels of gefitinib by increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Separate gefitinib and H2-antagonist doses by at least 6 hr."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glipizide",
            "description": {
                "common": "ibuprofen/famotidine will increase the level or effect of glipizide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glyburide",
            "description": {
                "common": "ibuprofen/famotidine will increase the level or effect of glyburide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iron dextran complex",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of iron dextran complex by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iron sucrose",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of iron sucrose by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "latanoprost",
            "description": {
                "common": "latanoprost, ibuprofen/famotidine. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "latanoprostene bunod ophthalmic",
            "description": {
                "common": "latanoprostene bunod ophthalmic, ibuprofen/famotidine. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ledipasvir/sofosbuvir",
            "description": {
                "common": "ibuprofen/famotidine decreases levels of ledipasvir/sofosbuvir by Other (see comment). Use Caution/Monitor. \nComment: Ledipasvir solubility decreases as pH increases; drugs that increase gastric pH are expected to decrease levels of ledipasvir; H2-receptor antagonists may be administered simultaneously with or 12 hr apart from ledipasvir/sofosbuvir at a dose that does not exceed doses comparable to famotidine 40 mg BID."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mesalamine",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of mesalamine by  increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylphenidate",
            "description": {
                "common": "ibuprofen/famotidine will increase the level or effect of methylphenidate by  increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Applies only to extended release formulation"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mifepristone",
            "description": {
                "common": "ibuprofen/famotidine, mifepristone.\nEither increases toxicity of the other by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mycophenolate",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of mycophenolate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of nelfinavir by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nilotinib",
            "description": {
                "common": "ibuprofen/famotidine decreases levels of nilotinib by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Avoid this interaction by administering H2 antagonists 10 hr after or 2 hr before nilotinib."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "polysaccharide iron",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of polysaccharide iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "posaconazole",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of posaconazole by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium iodide",
            "description": {
                "common": "potassium iodide and ibuprofen/famotidine both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prasugrel",
            "description": {
                "common": "ibuprofen/famotidine, prasugrel.\nEither increases effects of the other by anticoagulation. Use Caution/Monitor. Chronic use of NSAIDs with prasugrel may increase bleeding risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rilpivirine",
            "description": {
                "common": "ibuprofen/famotidine, rilpivirine. increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Combination of rilpivirine and H2-receptor antagonists should be used with caution as coadministration may cause significant decreases in rilpivirine plasma concentrations (increase in gastric pH). Administer famotidine at least 12 hours before or at least 4 hours after rilpivirine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rose hips",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of rose hips by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saquinavir",
            "description": {
                "common": "ibuprofen/famotidine will increase the level or effect of saquinavir by  unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "serdexmethylphenidate/dexmethylphenidate",
            "description": {
                "common": "ibuprofen/famotidine will increase the level or effect of serdexmethylphenidate/dexmethylphenidate by  increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Applies only to extended release formulation"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/?magnesium sulfate/potassium chloride",
            "description": {
                "common": "sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of ibuprofen/famotidine by Other (see comment). Use Caution/Monitor. \nComment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate",
            "description": {
                "common": "sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of ibuprofen/famotidine by Other (see comment). Use Caution/Monitor. \nComment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sofosbuvir/velpatasvir",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of sofosbuvir/velpatasvir by  increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Velpatasvir solubility decreases as gastric pH increases (practically insoluble at pH >5). H2 receptor antagonists may be administered simultaneously with or 12 hr apart from sofosbuvir/velpatasvir at a dose that does not exceed doses comparable to famotidine 40 mg BID."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sparsentan",
            "description": {
                "common": "ibuprofen/famotidine and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tafluprost",
            "description": {
                "common": "tafluprost, ibuprofen/famotidine. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "ibuprofen/famotidine will increase the level or effect of tolbutamide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "travoprost ophthalmic",
            "description": {
                "common": "travoprost ophthalmic, ibuprofen/famotidine. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "ibuprofen/famotidine, triamcinolone acetonide injectable suspension.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Concomitant use of NSAIDS and corticosteroids increases the risk of gastrointestinal side effects. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vandetanib",
            "description": {
                "common": "vandetanib increases levels of ibuprofen/famotidine by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Vandetanib inhibits the uptake of substrates of organic cation transporter type 2 (OCT2)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "varenicline",
            "description": {
                "common": "ibuprofen/famotidine will increase the level or effect of varenicline by  decreasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vismodegib",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of vismodegib by  Other (see comment). Use Caution/Monitor. Drugs that increase gastric pH alter vismodegib solubility and therefore reduce bioavailability; effect on efficacy unknown"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin, ibuprofen/famotidine.\nEither increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zanubrutinib",
            "description": {
                "common": "ibuprofen/famotidine, zanubrutinib.\nEither increases effects of the other by anticoagulation. Modify Therapy/Monitor Closely. Zanubrutinib-induced cytopenias increases risk of hemorrhage. Coadministration of zanubritinib with antiplatelets or anticoagulants may further increase this risk."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alendronate",
            "description": {
                "common": "ibuprofen/famotidine increases levels of alendronate by unspecified interaction mechanism. Minor/Significance Unknown. Monitor for increase in alendronate side effects."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "ibuprofen/famotidine decreases levels of aripiprazole by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "axitinib",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of axitinib by  increasing gastric pH. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "blessed thistle",
            "description": {
                "common": "blessed thistle decreases effects of ibuprofen/famotidine by pharmacodynamic antagonism. Minor/Significance Unknown. Theoretical interaction."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ceftibuten",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of ceftibuten by  increasing gastric pH. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyanocobalamin",
            "description": {
                "common": "ibuprofen/famotidine decreases levels of cyanocobalamin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "devil's claw",
            "description": {
                "common": "devil's claw decreases effects of ibuprofen/famotidine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "melphalan",
            "description": {
                "common": "ibuprofen/famotidine decreases levels of melphalan by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metformin",
            "description": {
                "common": "ibuprofen/famotidine increases levels of metformin by decreasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phytoestrogens",
            "description": {
                "common": "ibuprofen/famotidine decreases levels of phytoestrogens by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": "6"
        },
        {
            "name": "Dyspepsia",
            "percent": "5"
        },
        {
            "name": "Diarrhea",
            "percent": "5"
        },
        {
            "name": "Constipation",
            "percent": "4"
        },
        {
            "name": "Headache",
            "percent": "3"
        },
        {
            "name": "Hypertension",
            "percent": "3"
        },
        {
            "name": "Upper abdominal pain",
            "percent": "3"
        },
        {
            "name": "Gastroesophageal reflux",
            "percent": "2"
        },
        {
            "name": "Vomiting",
            "percent": "2"
        },
        {
            "name": "Stomach discomfort",
            "percent": "2"
        },
        {
            "name": "Anemia",
            "percent": "2"
        },
        {
            "name": "Peripheral edema",
            "percent": "2"
        }
    ]
}